Doses of Lilly's blockbuster GLP-1 in shortage have been pulled from FDA...
Doses of Eli Lilly’s blockbuster weight loss and diabetes drugs that were listed as in short supply no longer are, according to the FDA’s database that tracks drugs in limited supply. The agency’s...
View ArticleAdvisory committee votes in favor of Zevra Therapeutics' rare genetic disease...
A panel of outside advisors to the FDA voted 11-5 in favor of Zevra Therapeutics’ drug for a rare genetic condition called Niemann-Pick disease type C, saying that it is effective based on current...
View ArticleEisai’s new Leqembi data; Jim Wilson’s next move; Roivant dealmaker’s payday;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleNuvation pauses BET inhibitor plans after checking out interim Phase 1 data
Nuvation Bio won’t take its cancer drug NUV-868 into a Phase 2 trial for now, following a look at interim safety and efficacy data from a Phase 1 trial. The disclosure came in the biotech’s...
View ArticleEliot Forster’s pain biotech unveils Phase 2 data in degenerative joint disease
UK biotech Levicept said its first-in-class biologic can help ease pain and stiffness in patients with moderate to severe osteoarthritis, according to mid-stage data released Tuesday. The Phase 2...
View ArticleClik here to view.
BioMarin scales back launch for hemophilia gene therapy, pitches path to...
BioMarin Pharmaceutical is reeling in its gene therapy ambitions. On Monday, the company announced that it’s lowering spending plans for its hemophilia gene therapy, Roctavian, and stopping development...
View ArticleExclusive: Biotech investor Sofinnova hires former Biogen medical chief
Maha Radhakrishnan, who left her post as chief medical officer at Biogen earlier this year, is now an executive partner at Sofinnova Investments, the firm exclusively told Endpoints News. Radhakrishnan...
View ArticleClik here to view.
Ultimovacs’ cancer vaccine UV1 flunks Phase 2 head and neck cancer trial
For a second time this year, Ultimovacs saw its stock crash after reporting its cancer vaccine failed in a Phase 2 study in head and neck squamous cell carcinoma. Topline data from the Phase 2 FOCUS...
View ArticleBayer details 3,200 job cuts so far, spotlights ‘momentum’ in pharma pipeline
Bayer is “on track” to realize the €2 billion in cost savings it’s aiming for in 2026, executives say, even as they report another quarter of “modest” performance across its crop science,...
View ArticleA new Apple Tree Partners biotech launches with $55M to make ‘pan-variant’...
Red Queen Therapeutics is emerging from stealth with $55 million from venture capital group Apple Tree Partners, and plans to develop treatments for a swathe of viral infections including Covid-19 and...
View ArticleClik here to view.
Merck enlists partner Daiichi Sankyo to develop T cell engager from Harpoon...
Daiichi Sankyo is paying Merck $170 million upfront to snag joint development and commercialization rights to a Phase 1/2 T cell engager that the New Jersey pharma giant got in its Harpoon acquisition...
View ArticleJapanese government grants Shinobi $59M for cell therapy development
Cell therapy biotech Shinobi Therapeutics has pulled in $59 million in funding from a Japanese government grant. The pharma company also expanded its Series A round from last year. The Japanese Agency...
View ArticleClik here to view.
Exclusive: TCG, DCVC and Lux back new autoimmune biotech from Kallyope...
A stealth biotech from repeat collaborators has assembled the latest industry megaround. New York-based NILO Therapeutics has put together a $101 million Series A, Tim Kutzkey, a board member and...
View ArticleGenentech partners with cash-strapped Sangamo on epigenetic Alzheimer’s therapy
An experimental Alzheimer’s drug and its designer are getting a second chance. On Tuesday, Sangamo announced it had partnered with Genentech to develop an epigenetic repressor to prevent the production...
View ArticleClik here to view.
Hims takes steps to lock up drug supply for its booming weight loss business
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Hims CEO Andrew Dudum did his best Monday to reassure investors that the digital health startup’s...
View ArticleArie Belldegrun and team unveil $600M life sciences credit firm amid...
A new $600-plus million credit firm was unveiled Tuesday morning from Arie Belldegrun and other well-known life sciences names. Rather than create another venture capital firm, the Kite Pharma founder...
View ArticleClik here to view.
Exclusive: Covid and epidemic threat biotech Aerium Therapeutics closes after...
Aerium Therapeutics has ceased operations, ending its mission to bring to market new antibodies to protect immunocompromised people from Covid-19, develop highly sought-after long Covid treatments and...
View ArticleBioCryst culls Factor D inhibitor; Elevation Oncology’s stock plummets
Plus, news about Tenax Therapeutics: BioCryst discontinues Factor D inhibitor: This is after finding that “clinical activity observed was less than other therapies on the market.” The company tried to...
View ArticleClik here to view.
Eisai picks SEED Therapeutics for molecular glue deal worth as much as $1.5B
Eisai is paying SEED Therapeutics an undisclosed amount upfront in a deal worth up to $1.5 billion to develop new ‘molecular glue’-based therapies for neurodegenerative diseases and cancer. The...
View ArticleBicycle Therapeutics focuses pipeline and streamlines leadership team
Bicycle Therapeutics spelled out its pipeline priorities on Tuesday, adding that it will be looking for collaborators for its immune-oncology pipeline. It is also narrowing its executive team. The...
View Article